PROFProfound Medical Corp.

Nasdaq profoundmedical.com


$ 9.35 $ -0.07 (-0.75 %)    

Wednesday, 14-Aug-2024 15:23:44 EDT
QQQ $ 463.74 $ 0.15 (0.03 %)
DIA $ 400.12 $ 2.30 (0.58 %)
SPY $ 543.85 $ 1.71 (0.32 %)
TLT $ 97.88 $ 0.61 (0.63 %)
GLD $ 226.19 $ -1.86 (-0.82 %)
$ 9.31
$ 9.31
$ 9.35 x 100
-- x --
$ 9.31 - $ 9.39
$ 7.11 - $ 11.69
14,450
na
198.96M
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 profound-reiterates-guidance
Profound Reiterates Guidance
08/08/2024 21:55:17

Current 2024 OutlookAs previously disclosed, based on the Company's current business planning and budgeting activities, Pro...

 profound-medical-q2-2024-gaap-eps-028-beats-030-estimate-sales-2233m-beat-2100m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0....

 stifel-upgrades-profound-medical-to-buy-raises-price-target-to-12

Stifel analyst Rick Wise upgrades Profound Medical (NASDAQ:PROF) from Hold to Buy and raises the price target from $9 to $12.

 profound-medical-q1-2024-gaap-eps-026-beats-030-estimate-sales-1910m-miss-2521m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0....

Core News & Articles

— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings arou...

 alliance-global-partners-maintains-buy-on-profound-medical-lowers-price-target-to-108

Alliance Global Partners analyst Ben Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lowers the price target ...

 stifel-maintains-hold-on-profound-medical-lowers-price-target-to-9

Stifel analyst Rick Wise maintains Profound Medical (NASDAQ:PROF) with a Hold and lowers the price target from $11 to $9.

 profound-medical-q4-2023-gaap-eps-0420-misses-0330-estimate-sales-2000m-beat-1977m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.420) per share which missed the analyst consensus estimate of $...

 earnings-scheduled-for-march-7-2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

 profound-medical-announces-non-brokered-private-placement-for-gross-proceeds-of-2937507-expects-to-issue-391667-common-shares-at-750share

The closing of the Private Placement is expected to occur on or about January 17, 2024, subject to customary closing conditions.

 alliance-global-partners-maintains-buy-on-profound-medical-lowers-price-target-to-1275

Alliance Global Partners analyst Ben Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lowers the price target ...

Core News & Articles

Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device ...

 chord-energy-profound-medical-and-3-stocks-to-watch-heading-into-thursday

With U.S. stock futures trading slightly higher this morning on Thursday, some of the stocks that may grab investor focus today...

 profound-medical-prices-20m-public-offering-of-2666667-common-shares-at-750share

The Offering is expected to close on or about January 2, 2024.

 profound-medical-announces-proposed-public-offering-of-common-shares-terms-not-disclosed

The Company intends that the Offering will be priced in the context of the market, with such price and the total size of the Of...

 stifel-initiates-coverage-on-profound-medical-with-hold-rating-announces-price-target-of-11

Stifel analyst Rick Wise initiates coverage on Profound Medical (NASDAQ:PROF) with a Hold rating and announces Price Target ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION